Margo De Velder

Lipid nanoparticles massively target myeloid cells upon infusion. We will further explore these interesting findings by exploring the use of mRNA LNPs for the in situ generation of Chimeric Antigen Receptor (CAR)-Ms. CAR-Ms were recently identified as a highly interesting alternative for CAR-T cells as they can more effectively penetrate solid tumors thereby reducing tumor burden and boosting T-cell mediated immunity. 
 

Margo De Velder started her Bachelor in Pharmaceutical Sciences at Ghent University in 2017, and obtained her master’s degree in Drug Development in 2022 with great distinction. She performed her master’s thesis in 2021 at the Laboratory of General Biochemistry and Physical Pharmacy (FFW, Ghent University) with the title: ‘Predicting the fate of intravenously injected liposomes in vivo: exploiting an ex vivo whole blood uptake assay for innate immune cell interactions’.
In October 2022, Margo started her PhD at the laboratory of General Biochemistry and Physical Pharmacy under the supervision of Prof. Stefaan De Smedt and Dr. Ine Lentacker. 
 

• Lab address: Campus Heymans, Ottergemse Steenweg 460, 9000 Gent, Belgium
• Margo De Velder is interested to receive invitations for talks and presentations